Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: miyawaki h. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. Tanzawa S, et al. Among authors: miyawaki h. Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: 10.1177/1758835921998588. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717228 Free PMC article.
Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy.
Kanaji N, Shimizu J, Sakai K, Ueda Y, Miyawaki H, Watanabe N, Uemura T, Hida T, Inoue T, Watanabe N, Oohara Y, Dobashi H, Kato M, Kadowaki N. Kanaji N, et al. Among authors: miyawaki h. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963866. doi: 10.1177/1753466620963866. Ther Adv Respir Dis. 2020. PMID: 33086985 Free PMC article.
Asthma mortality based on death certificates: A demographic survey in Kagawa, Japan.
Kamei T, Kanaji N, Nakamura H, Arakawa Y, Miyawaki H, Kishimoto N, Suzaki N, Yamamoto A, Nanki N, Yamazaki Y, Ishii T, Kohi F, Hirao T, Fujita J, Bandoh S, Hoshikawa Y. Kamei T, et al. Among authors: miyawaki h. Respir Investig. 2019 May;57(3):268-273. doi: 10.1016/j.resinv.2019.02.002. Epub 2019 Mar 1. Respir Investig. 2019. PMID: 30833156
Hepatocyte growth factor and digital clubbing.
Hojo S, Fujita J, Yamadori I, Ezaki T, Watanabe S, Yamanouchi H, Miyawaki H, Yamaji Y, Nishioka M, Takahara J. Hojo S, et al. Among authors: miyawaki h. Intern Med. 1997 Jan;36(1):44-6. doi: 10.2169/internalmedicine.36.44. Intern Med. 1997. PMID: 9058100 Free article.
161 results